Notice ID: 551e9985e0134904b42f8023aa869d65Presolicitation
Proteomics study using Olink Reveal Kits
Archived on July 11, 2026. Original response deadline: . Full description on SAM.gov.
Description
The Center for Research on Genomics and Global Health (CRGGH) explores how genetic and environmental factors contribute to the onset of complex diseases like Type 2 diabetes, obesity, and hypertension. Over the past two decades, CRGGH has gathered phenotypic data from more than 6,000 individuals both in the United States and internationally.
To better understand the underlying causes of metabolic disorders, CRGGH researchers utilize a variety of analytical methods. Over the years, they have systematically collected diverse types of -omics data, including genomics, transcriptomics, proteomics and microbiomes—from all or some participants, aiming to conduct integrated analyses that unravel underpinning mechanisms of these diseases.
Overview
Agency:
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Office:NATIONAL INSTITUTES OF HEALTH OLAO
Posted:June 16, 2026
NAICS:325414: Biological Product (except Diagnostic) Manufacturing
Last Updated:Aug 21, 2026
PSC:6505: DRUGS AND BIOLOGICALS
Set-Aside:Not specified
Type:Presolicitation
Place of Performance:Bethesda, Maryland, 20892
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
LAW, JAMES B
Documents
No documents available.
Lifecycle
Solicitation:
75N98026Q00642- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- Pre-SolicitationCurrentJun 16, 2026
Proteomics study using Olink Reveal Kits
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for a purchase order NTE $900,000 for FDA-approved radiopharmaceuticals for patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences at the NIH Clinical Center. CARDINAL HEALTH is a reputed and reliable FDA and US NRC vetted supplier of the required radiopharmaceuticals by the Clinical Center. Based on the past 25 years of contracting with this vendor, this vendor is the only acceptable vendor because they provide a comprehensive list of radiopharmaceuticals that uniquely meets the patient needs of the NIH Clinical Center. They are the only provider that can supply all radiopharmaceuticals that emit gamma, positrons, beta and/or alpha radiations. They also use a patented tungsten delivery system for dispensing the high energy positron radiopharmaceuticals. This system minimizes radiation exposure to the staff and the public, as well as meeting the weight standard that reduces the potential weightlifting injuries to the staff. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.500 This subpart authorizes the use of simplified procedures for the acquisition of supplies and services in amounts greater than the simplified acquisition threshold but not exceeding $9 million ($15 million for acquisitions as described in 13.500(c)), including options, if the contracting officer reasonably expects, based on the nature of the supplies or services sought, and on market research, that offers will include only commercial products or commercial services. Contracting officers may use any simplified acquisition procedure in this part, subject to any specific dollar limitation applicable to the particular procedure. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date. Notice Type: Notice of Intent NAICS Code: 325412 PSC Code: 3650 Posted Date: 10/13/2026 Close Date: 10/19/2026 12pm EST End User IC: Clinical Center POC Name: Ryssa Nix Email Address: Ryssa.nix@nih.gov | Pre-Solicitation | 325412 | No Set-Aside | 10/13/2026 | 10/19/2026 | Bethesda, MD | |
The Defense Health Agency Contracting Activity (DHACA) on behalf of the Walter Reed Army Institute of Research (WRAIR), intends to negotiate on a sole source basis in accordance with FAR 6.302 with vendor Lampire Biological Labs, Inc., 3599 Farm School Rd, Ottsville, PA 18942-1536 The contractor shall supply 48 units (50ml per bottle equals one unit) of defibrinated rabbit blood per period of performance, base year plus four (one-year) option periods. Each unit shall have a lot number and associated product data sheet. Product shall be packaged to protect from damage during shipping, prevent leaks or spillage, comply with appropriate shipping regulations, and maintain temperature of 2-8 degrees Celsius upon arrival at destination. | Special Notice | 325414 | No Set-Aside | 10/08/2026 | 10/23/2026 | Silver Spring, MD | |
The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA’s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. Vascular Solutions, LLC is the only source able to meet the Government’s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ™, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark. Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil. | Special Notice | 325412 | No Set-Aside | 09/01/2026 | 09/16/2026 | - | |
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Part 12. This announcement constitutes the only solicitation. Proposals are being requested and a separate written solicitation will not be issued. Solicitation number 12639527R0001 is issued as a Request for Proposal (RFP) for the purchase and storage of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), conversion of Government owed VAC into usable vaccine, and the direct purchase of finished vaccine. This acquisition is not set-aside for small business concerns. The applicable North American Industry Classification Standard Code is 325414. The small business size standard is 1,250. This acquisition is an unrestricted requirement. All responsible sources may submit a proposal which will be considered by the agency. | Combined Synopsis | 325414 | No Set-Aside | 10/01/2026 | 11/10/2026 | Ames, IA | |
The following VISN 12 Locations have a need for delivery of Blood and Blood Products. Jesse Brown VAMC, 820 South Damen Ave, Chicago, IL 60612 Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064 Hines VAMC, 5000 South 5th Ave, Hines, IL 60141 William S Middleton VAMC, 2500 Overlook Terrace, Madison, WI 53705. Tomah VAMC, 500 E. Veterans Street, Tomah, WI 54660 Zablocki VAMC, 5000 W. National Ave, Milwaukee WI 53295. The Blood and Blood Products will be defined in RFQ# 36C25226Q0606. | Awarded | 325414 | No Set-Aside | 09/30/2026 | Open | - |
Additional Details
Solicitation Number
75N98026Q00642
Archive Date
Jul 11, 2026
Office Address
BETHESDA, MD, 20892